| NLGN1 |
gene |
3 |
2 |
Neuroligin 1 |
| NLGN3 |
gene |
3 |
2 |
NL3, Neuroligin 3, Neuroligin-3, neuroligin-3 |
| NLRP3 |
gene |
4 |
3 |
NLR family pyrin domain containing 3, NLRP3 inflammasome, NLRP3 receptor, Nlrp3 |
| NMDA |
drug |
7 |
7 |
N-methyl-D-aspartate, NMDA, NMDA receptor, NMDA receptors, synthetic agonist NMDA |
| NMDAR |
drug |
9 |
7 |
N-methyl-D-aspartate receptor, N-methyl-d-aspartate receptor, NMDA, NMDA receptor, NMDAR signalling, NMDAR-mediated activity, NMDARs |
| NMDA receptor |
drug |
25 |
21 |
N-methyl-D-aspartate receptor, N-methyl-d-aspartic acid receptor, NMDA, NMDA receptor activity, NMDA receptors, NMDA system, NMDAR, NMDARs |
| NNAT |
gene |
2 |
2 |
Neuronatin |
| NO |
drug |
3 |
3 |
nitric oxide |
| NoGo |
phenotype |
2 |
1 |
NoGo, NoGo condition, NoGo stimulus, suppression |
| NoGo condition |
phenotype |
3 |
3 |
NoGo, NoGo trials, response inhibition |
| nonalcoholic |
cohort |
5 |
— |
control subject, non-drinker, nonalcoholic |
| Non-alcoholic fatty liver disease |
phenotype |
5 |
1 |
NAFLD, NASH, non-alcoholic fatty liver diseases |
| Nonalcoholics |
cohort |
4 |
2 |
controls, non-alcoholic individuals, non-alcoholics, nonalcoholics |
| nonassaultive trauma |
phenotype |
3 |
2 |
nonassaultive, nonassaultive events, nonassaultive trauma, non‑assaultive trauma |
| non-coding RNA |
drug |
3 |
1 |
ncRNA |
| non-coding variant |
cohort |
3 |
2 |
non-coding variants |
| noncoding variant |
variant |
3 |
2 |
RegulomeDB-predicted variants, noncoding variants |
| non-communicable disease |
phenotype |
2 |
2 |
NCD, NCDs, non-communicable diseases |
| non-drinkers |
phenotype |
11 |
2 |
NAC, NAC group, never drinkers, non-alcoholic subjects, non-drinkers, nonalcoholics |
| non-essential amino acids |
drug |
6 |
3 |
NEAA, NEAA-1X |
